{"acute kidney injury": 2.69, "acute respiratory distress syndrome": 2.61, "anaphylactic reaction": 4.84, "anaphylactic shock": 2.1, "anaphylactoid reaction": 22.0, "anti factor viii antibody positive": 24.81, "autoimmune haemolytic anaemia": 14.58, "bacteraemia": 3.95, "blood immunoglobulin g decreased": 31.3, "blood lactate dehydrogenase increased": 2.29, "cardiogenic shock": 3.44, "chronic hepatitis b": 64.45, "coombs direct test positive": 155.53, "coronary artery aneurysm": 117.2, "cytomegalovirus infection": 3.8, "deep vein thrombosis": 2.45, "drug dependence": 2.94, "drug effective for unapproved indication": 155.37, "drug ineffective": 7.08, "drug ineffective for unapproved indication": 179.84, "drug intolerance": 3.25, "drug reaction with eosinophilia and systemic symptoms": 2.38, "drug resistance": 6.13, "dyshidrotic eczema": 24.33, "ear infection": 4.51, "embolism": 4.17, "epstein-barr virus infection": 5.08, "exposure during pregnancy": 11.55, "febrile nonhaemolytic transfusion reaction": 154.53, "foetal death": 8.65, "foetal exposure during pregnancy": 11.0, "haemolysis": 43.11, "haemolytic anaemia": 53.6, "hepatitis b": 31.27, "hepatitis b core antibody positive": 61.17, "hepatitis b surface antibody positive": 72.01, "hepatitis c": 7.36, "hypervolaemia": 4.55, "hypotension": 2.46, "hypoxia": 4.74, "incorrect drug administration rate": 20.57, "infusion related reaction": 4.27, "infusion site erythema": 12.58, "infusion site pain": 9.1, "intentional product use issue": 14.63, "ischaemic stroke": 2.09, "jaundice": 3.03, "low birth weight baby": 5.14, "maternal exposure during pregnancy": 4.32, "meningitis": 3.56, "meningitis aseptic": 124.51, "misleading laboratory test result": 728.86, "myositis": 2.73, "nephrotic syndrome": 2.54, "no adverse event": 46.01, "off label use": 7.56, "posterior reversible encephalopathy syndrome": 22.62, "premature baby": 7.95, "premature delivery": 4.78, "product use in unapproved indication": 10.23, "pulmonary embolism": 2.57, "respiratory distress": 2.26, "respiratory failure": 2.37, "shock": 2.03, "stress cardiomyopathy": 8.31, "suspected counterfeit product": 10.87, "tachypnoea": 5.58, "therapeutic product effect incomplete": 28.69, "therapeutic response decreased": 2.1, "therapeutic response unexpected": 18.13, "therapy non-responder": 19.06, "therapy partial responder": 12.8, "toxic epidermal necrolysis": 3.06, "transfusion-related acute lung injury": 356.63, "transfusion-related circulatory overload": 260.18, "treatment failure": 2.45, "vertical infection transmission": 877.58}